Summary
This communication focuses on the problems that exist in the application of cell kinetic information in cancer chemotherapy. From selected historical work, the following conclusions can be drawn.
-
1
Theoretically optimal drug sequences may fail to show the expected effect.
-
2
Similar drug sequences cause different effects in different tumors, even when the tumors have similar proliferation characteristics.
The unpredictability and the heterogeneity in response make the extrapolation to clinical cancer chemotherapy very difficult. Better prediction may be made from the integration of results from studies combining cell kinetic factors, cellular pharma- cokinetics, and biochemistry of drug exposure.
Supported by the Koningin Wilhelmina Fonds, Netherlands Organization for the Fight against Cancer, by grant number 5 PO1CA13053-05, awarded by the National Cancer Institute, DHEW, and by Premeso
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Avery TL, Roberts D (1974) Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210. Eur J Cancer 10:425–429
Bruce WR, Meeker BE, Valeriote FA (1966) Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37:233–245
DeWys WD, Goldin A, Mantel N (1970) Hematopoietic recovery after large doses of cyclophosphamide: Correlation of proliferation state with sensitivity. Cancer Res 30:1692–1697
Edelstein M, Vietti T, Valeriote F (1974) Schedule-dependent synergism for the combination of l-/?-D-arabinofuranosylcytosine and daunorubicin. Cancer Res 34:293–297
Edelstein M, Vietti T, Valeriote F (1975) l-/?-D-Arabinofuranosylcytosine and methotrex- ate. Cancer Res 35:1555–1558
Goldenberg GJ (1974) Drug-induced stimulation of nitrogen mustard and choline transport and other systems in L5178Y lymphoblasts in vitro. Cancer Res 34:2511–2516
Goldie JH, Price LA, Harrap KR (1972) Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion pattern. Eur J Cancer 8:409–414
Hill BT, Baserga R (1975) The cell cycle and its significance for cancer treatment. Cancer Treat Rev 2:159–175
Klein HO (1972) Synchronization of tumour cell proliferation and the timing of cytostatic drugs. Biomedicine 17:835–838
Klein HO, Lennartz KJ (1974) Chemotherapy after synchronization of tumour cells. Semin Hematol 11:203–227
Klein HO, Lennartz KJ, Habicht W, Eder M, Gross R (1970) Synchronisation von Ehrlich-Ascites-Tumorzellen und ihre Bedeutung bei der Anwendung eines alkylierenden Cytostaticums. Klin Wochenschr 48:1001–1005
Lamerton LF (1972) Cell proliferation and the differential response of normal and malignant tissues. Br J Radiol 45:161–170
Mauer AM (1973) Effects of chemotherapeutic agents on cell cycle and cellular proliferation: Basic and clinical considerations. Transplant Proc 5:1181–1184
Mulder JH, Lelieveld P, Van Putten LM (1979) Lack of vincristine-cyclophosphamide potentiation in different experimental tumour lines. Eur J Cancer 15:499–507
Mulder JH, Smink T, Van Putten LM (1977) Schedule dependent effectiveness of CCNU and 5-fluorouracil in experimental chemotherapy. Eur J Cancer 13:1123–1131
Nicolini C (1976) The principles and methods of cell synchronization in cancer chemotherapy. BBA Rev Cancer 458:243–283
Pouillart P, Hoang Thy Huong T, Brugerie E, Lheritier J (1974) Sequential administration of two oncostatic drugs: Study of modalities for pharmacodynamic potentiation. Biomedicine 21:471–479
Rajewsky MF (1975) Proliferative parameters relevant to cancer therapy. In: Grundman E, Gross R (eds) The ambivalence of cytostatic therapy. Springer, Heidelberg, pp 156–171
Razek A, Vietti T, Valeriote F (1974) Optimum time sequence for the administration of vincristine and cyclophosphamide in vivo. Cancer Res 34:1857–1861
Schabel FM Jr (1975) Synergism and antagonism among antitumor agents. In: Pharmacological basis of cancer chemotherapy. Williams and Wilkins, Baltimore, pp 595–621
Tattersall MHN, Harrap KR (1973) Combination chemotherapy: The antagonism of methotrexate and cytosine arabinoside. Eur J Cancer 9:229–232
Tubiana M, Frindel E, Vassort F (1975) Critical survey of experimental data on in vivo synchronization by hydroxyurea. In: Grundman E, Gross R (eds) The ambivalence of cytostatic therapy. Springer, Heidelberg, pp 187–205
Valeriote F, Van Putten LM (1975) Proliferation-dependent cytotoxicity of anticancer agents: A review. Cancer Res 35:2619–2630
Van Putten LM, Keizer HJ, Mulder JH (1976) Synchronization in tumour chemotherapy. Eur J Cancer 12:79–85
Volm M, Krieg L, Mattern J, Wayss K (1977) Effect of synchronization on chemotherapy of solid transplanted tumours. Eur J Cancer 13:1099–1108
Zeller WJ, Ivankovic S, Schmahl D (1975) Chemotherapy of the transplantable acute leukemia L5222 in rats. Cancer Res 35:1168–1174
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lelieveld, P., Mulder, J.H., Edelstein, M.B., van Putten, L.M. (1980). Cell Kinetic Factors, Single Drugs and Combination. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 74. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81488-4_33
Download citation
DOI: https://doi.org/10.1007/978-3-642-81488-4_33
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81490-7
Online ISBN: 978-3-642-81488-4
eBook Packages: Springer Book Archive